A longitudinal study showed of patients with treatment-resistant depression undergoing anti-inflammatory treatment with the tumor necrosis factor antagonist infliximab identified peripheral blood gene transcripts enriched for oxidative stress and mitochondrial degradation, which were related to increases in psychomotor reaction time (55). This evidence concerns the gene TNF and depressive symptom measurement.